Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

NCT04836728 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Metastatic
First-line Treatment

Interventions

BIOLOGICAL: CIK cells injection
DRUG: Sintilimab Injection
DRUG: Pemetrexed
DRUG: Albumin paclitaxel
DRUG: Carboplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital